Drug Trial Radar · NCT01880424
A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Last checked: Nov 19, 2026Latest source record: Sep 27, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,722
Actual
Start
Jul 2013
Primary completion
May 2015
Study completion May 2015
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Ironwood Pharmaceuticals, Inc.
- First posted
- Jun 19, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is an international, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial comparing one dose of linaclotide to placebo. Approximately 800 patients with a diagnosis of IBS-C (modified Rome III criteria) will be randomized at up to 60 trial centers in China, Australia, and New Zealand. The trial will consist of up to 21 days of screening, 14 to 21 days of pre-treatment, 12 weeks of double-blind treatment, and 2 weeks of follow-up. At the end of the Pre-treatment Period, patients meeting the entry criteria for this trial will be randomized to one of two double-blind treatment groups: 290 ug linaclotide, or placebo (1:1).
Conditions
- Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
PlaceboDrug
matching Placebo Capsules, Oral, once daily
LinaclotideDrug
Linaclotide 290 ug Capsules, Oral, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- 12-week Abdominal Pain/Abdominal Discomfort Weekly ResponderTime frame: Baseline and Weeks 1-12 during the Treatment Period
- 12-week Irritable Bowel Syndrome (IBS) Degree of Relief ResponderTime frame: Baseline and Weeks 1-12 during the Treatment Period
Locations
82 sites in 5 countries. Site status is shown where the registry gives one.
Research Site
Huntsville, Alabama
Research Site
North Little Rock, Arkansas
Research Site
Phoenix, Arkansas
Research Site
Artesia, California
Research Site
Chula Vista, California
Research Site
Encino, California
Research Site
North Hollywood, California
Research Site
Orange, California
Research Site
Riverside, California
Research Site
San Diego, California
Research Site
Boynton Beach, Florida
Research Site
Brandon, Florida
Research Site
Brooksville, Florida
Research Site
Doral, Florida
Research Site
Gainesville, Florida
Research Site
Hialeah, Florida
Research Site
Kissimmee, Florida
Research Site
Lauderdale Lakes, Florida
Research Site
Miami, Florida
Research Site
Miami Lakes, Florida
Research Site
Addison, Illinois
Research Site
Evansville, Indiana
Research Site
Crowley, Louisiana
Research Site
Monroe, Louisiana
Research Site
Shreveport, Louisiana
Research Site
Boston, Massachusetts
Research Site
Chesterfield, Michigan
Research Site
Wyoming, Michigan
Research Site
St Louis, Missouri
Research Site
Billings, Montana
Research Site
Las Vegas, Nevada
Research Site
Brooklyn, New York
Research Site
Great Neck, New York
Research Site
New York, New York
Research Site
Raleigh, North Carolina
Research Site
Salisbury, North Carolina
Research Site
Winston-Salem, North Carolina
Research Site
Cincinnati, Ohio
Research Site
Dayton, Ohio
Research Site
Franklin, Ohio
Showing 40 of 82 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.